Search and analyze individual stocks with comprehensive metrics
Krebs Biochemicals and Industries Limited
Fundamental Score
Krebs Biochemicals and Industries Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of KREBSBIO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Suboptimal ROCE (-30.09%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-35.14%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Revenue Contraction (-57.49%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Earnings Growth (4.02% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (1.23% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Weak Interest Coverage (-3.34x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-132.65 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 0.50%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Krebs Biochemicals and Industries Limited
About KREBSBIO
Company Details
Market Information
Performance
KREBSBIO Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of KREBSBIO?
KREBSBIO is currently trading at ₹75.97 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of KREBSBIO shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of KREBSBIO and what does it mean?
KREBSBIO has a P/E ratio of N/Ax compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is KREBSBIO performing according to Bull Run's analysis?
KREBSBIO has a Bull Run fundamental score of 11.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: N/A%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does KREBSBIO belong to?
KREBSBIO operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Krebs Biochemicals and Industries Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for KREBSBIO?
KREBSBIO has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Krebs Biochemicals and Industries Limited generates profits from shareholders' equity. An ROE of N/A% means the company generates ₹N/A profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is KREBSBIO's debt-to-equity ratio and what does it indicate?
KREBSBIO has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk. This means the company has ₹0 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is KREBSBIO's dividend yield and is it a good dividend stock?
KREBSBIO offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has KREBSBIO grown over the past 5 years?
KREBSBIO has achieved 5-year growth rates of: Sales Growth 5.33%, Profit Growth 1.23%, and EPS Growth 4.02%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in KREBSBIO and why does it matter?
Promoters hold 72.74% of KREBSBIO shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does KREBSBIO compare with its industry peers?
KREBSBIO trades at P/E N/Ax vs industry average 33.97x, with ROE of N/A% and ROCE of -30.09%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether KREBSBIO is outperforming its competitive set in profitability, growth, and valuation metrics.
What is KREBSBIO's market capitalization and what category does it fall into?
KREBSBIO has a market capitalization of ₹164 crores, making it a Mid-cap stock. Mid-cap stocks balance growth potential with moderate risk. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for KREBSBIO?
Key ratios for KREBSBIO: ROE N/A% (Needs improvement), ROCE -30.09%, P/E N/Ax, Debt-to-Equity N/A, Interest Coverage -3.34x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is KREBSBIO stock and what is its beta?
KREBSBIO has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for KREBSBIO?
KREBSBIO has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹75.97, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in KREBSBIO?
Key risks for KREBSBIO include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: N/A), and operational challenges. The stock has a Fundamental Score of 11.4/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is KREBSBIO's operating profit margin and how has it trended?
KREBSBIO has a 5-year average Operating Profit Margin (OPM) of -35.14%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is KREBSBIO's quarterly performance in terms of sales and profit growth?
KREBSBIO's recent quarterly performance shows YoY Sales Growth of -57.49% and YoY Profit Growth of -2.90%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in KREBSBIO?
KREBSBIO has FII holding of 0.50% and DII holding of 0.00%, totaling 0.50% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.